-2%
Erloren is a kinase inhibitor, chemically named N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. It works by reversibly inhibiting the activity of the EGFR kinase, preventing the autophosphorylation of tyrosine residues, and blocking downstream signaling pathways. Erloren has a higher binding affinity for EGFR with exon 19 deletions or exon 21 (L858R) mutations than the wild-type receptor. Its effects on other tyrosine kinase receptors have not been fully characterized.
Erlotinib-
Non-Small Cell Lung Cancer (NSCLC):
- First-line treatment for patients with metastatic NSCLC whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations.
- Maintenance therapy for patients with locally advanced or metastatic NSCLC, whose disease has not progressed following four cycles of platinum-based first-line chemotherapy.
- Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
Pancreatic Cancer:
First-line treatment for patients with locally advanced, unresectable, or metastatic pancreatic cancer, in combination with gemcitabine.
Note: Use only as directed by a registered physician.